SONX

0.37170.00%
OB

Olav B. Bergheim

Executive Director

Mr. Olav B. Bergheim is President, CEO & Director of Metronom Health, Inc. Mr. Bergheim had been Chairman of Adagio Medical Holdings, Inc. since July 31, 2024 until December 13, 2024 and served as its Chief Executive Officer until December 13, 2024. He is the Founder of Adagio Medical Holdings, Inc. and was its President, Secretary and Executive Director. He has been Director of Anaxiom Corp. He serves as an CEO, Secretary and Director at YAP Therapeutics Inc. He serves as an Executive Officer at Otello Medical, Inc. He served as an Executive Officer at Metronom Health, Inc. He has experience in founding and managing life science companies. Mr. Bergheim serves as the Chairman of Kato Pharmaceuticals, Inc. Mr. Bergheim has experience in creating and managing life science companies. Mr. Bergheim founded Allegro Medical, Inc.; Anaxiom Corporation; Kato Pharmaceuticals, Inc.; Metronom Health, Inc.; Prelude Corporation; Sonendo, Inc.; Volante Diagnostics, Inc.; and YAP Therapeutics, Inc. Previously, Mr. Bergheim was General Partner of Domain Associates, where he started VenPro; 3F Therapeutics (acquired by Medtronic); Vessix Vascular (acquired by Boston Scientific); Volcano Therapeutics (acquired by Phillips); and Glaukos Corporation. Earlier, Mr. Bergheim spent 18 years in general management positions at Baxter Healthcare Corporations. He serves as Chairman of the Board and Secretray at Prelude Corporation. He is the Founder of Fjord Ventures LLC and serves as its Managing Director. He co-founded Sonendo, Inc. and serves as its Executive Director since June 2006. He co-founded Glaukos Corporation in 1998. He founded Volcano Corporation. He served as an Executive Officer of Baxter Healthcare Corporation. He served as Chief Executive Officer of Chimeric Therapies. Mr. Bergheim's vast experience in general management includes many years of general management experience at Baxter from 1977 to 1995, where he was the Corporate Vice President and the President of Cardiovascular Group at Baxter International Inc. Prior to the Cardiovascular Group, Mr. Bergheim served as the President at Immunotherapy Worldwide, BioTech Europe and Baxter Germany. After leaving Baxter, he served as a General Partner at Domain Associates, L.L.C. He Founded Lonestar Heart, Inc. in 2010 and serves as its Executive Chairman. He was the Chairman at CardioPolymers, Inc. He served as the Chairman of Vessix Vascular, Inc. and its Director from 2006 to 2012. He served as the Chairman of the Board of Orqis Medical Corporation and Symphony Medical. He served as the Chairman of Volcano Corporation from February 2001 to January 1, 2009. He serves as a Director of Windy Hill Medical Inc. and Metronom Health, Inc. Mr. Bergheim was also a Member of the Board at 3F Therapeutics, Inc., Vascular Architects, Inc., Venpro Corp., DiObex, Inc., Cadence Pharmaceuticals Inc. and Verus Pharmaceuticals, Inc. He served as Director of Brexys, Inc. He served as a Director of Glaukos Corporation from July 1998 to June 02, 2016. He served on the Boards of Sound Health Solutions, Inc. and iVow Inc. He served as a Director of Fusion Medical Technologies, Inc. since October 1995 and Volcano Corporation from 1999 to January 1, 2009. He has experience in creating and managing life science type companies. Mr. Bergheim obtained an M.S. and a B.S. in Pharmacy from the University of Oslo. He also attended the Executive M.B.A. Program at the University of Virginia's Darden School of Business Administration.

Positions